The patient is tested for all genetic mutations that are known to cause cancer, regardless of what type of tumor the patient has. In the example above, a patient with lung cancer has three genetic mutations linked to cancer. The Molecular Tumor Board then uses these genetic mutations to consider possible treatment options for the patient.
Each genetic mutation is evaluated for FDA-approved therapies for the patient’s tumor type, other FDA-approved therapies in other tumor types and any clinical trials available related to the specific genetic mutations. Taking into consideration the total treatment options available, the Molecular Tumor Board makes a treatment recommendation based on the best possible outcome for the patient.